The NIH news release Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released [1]: > An investigational COVID-19 vaccine de

The NIH news release Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released [1]: > An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator for months. > The interim analysis assessed 468 cases of symptomatic COVID-19 among 44,325 adult volunteers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, and the United States. The investigational vaccine was reportedly 66% effective at preventing the study’s combined endpoints of moderate and severe COVID-19 at 28 days post-vaccination among all volunteers, including those infected with an emerging viral variant. [1] https://www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released https://www.nih.gov/news-events/news-releases/janssen-invest...